当前位置： SCI文献检索 > Pulmonary Circulation期刊下所有文献 > Effects of dose and age on adverse events associated with tadalafil in the treatment of pulmonary arterial hypertension.

Effects of dose and age on adverse events associated with tadalafil in the treatment of pulmonary arterial hypertension.

Abstract：

:There are limited data on the management of pulmonary arterial hypertension (PAH) in the elderly; therefore, this analysis compared the safety and efficacy of tadalafil between patients ≥65 and <65 years old. This was a post hoc analysis of the randomized, double-blind, placebo-controlled phase 3 Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST-1) study. Patients who completed the 16-week study or who discontinued because of clinical worsening and were not receiving tadalafil 40 mg were eligible for a long-term, open-label extension study. Adverse events (AEs) and efficacy outcomes were assessed in patients ≥65 versus <65 years old, and the dose dependency of common AEs was determined. Twenty-eight percent (112 of 405) of patients were ≥65 years of age (mean in this subset, 72 ± 5 years). Compared with younger patients, elderly patients were more likely to be World Health Organization functional class III/IV (75% vs. 65%, respectively) and to have lower exercise capacity as assessed by 6-minute walk distance (6MWD; mean, 299 vs. 366 m). Compared with placebo, tadalafil increased 6MWD by a mean of 35 and 43 m in patients ≥65 and <65 years, respectively. Common AEs (including headache, dyspepsia, and myalgia) were similar in both groups and tended to decrease in incidence with longer treatment duration. No differences in AEs were observed between elderly patients who received tadalafil 20 or 40 mg. In conclusion, the safety and efficacy of tadalafil for treatment of PAH are similar between elderly patients and patients <65 years old.

journal_name

Pulm Circ

journal_title

Pulmonary circulation

authors

Berman-Rosenzweig E,Arneson C,Klinger JR

doi

10.1086/674901

subject

Has Abstract

pub_date

2014-03-01 00:00:00

pages

45-52

issue

1

eissn

2045-8932

issn

2045-8940

pii

PC2013035

journal_volume

4

pub_type

杂志文章

相关文献

Pulmonary Circulation文献大全
  • Plasma acylcarnitines are associated with pulmonary hypertension.

    abstract：:Quantifying metabolic derangements in pulmonary hypertension (PH) by plasma metabolomics could identify biomarkers useful for diagnosis and treatment. The objective of this paper is to test the hypotheses that circulating metabolites are differentially expressed in PH patients compared with controls and among differen...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1086/690554

    authors： Luo N,Craig D,Ilkayeva O,Muehlbauer M,Kraus WE,Newgard CB,Shah SH,Rajagopal S

    更新日期：2017-02-01 00:00:00

  • BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension (2017 Grover Conference Series).

    abstract：:Despite the discovery more than 15 years ago that patients with hereditary pulmonary arterial hypertension (HPAH) inherit BMP type 2 receptor ( BMPR2) mutations, it is still unclear how these mutations cause disease. In part, this is attributable to the rarity of HPAH and difficulty obtaining tissue samples from patie...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1177/2045894018765840

    authors： Frump A,Prewitt A,de Caestecker MP

    更新日期：2018-04-01 00:00:00

  • Inspiratory capacity is not altered in operable chronic thromboembolic pulmonary hypertension.

    abstract：:Pathological alterations of inspiratory capacity (IC) have been observed in pulmonary hypertension. However, the clinical significance of IC in operable chronic thromboembolic pulmonary hypertension (CTEPH) without other pulmonary diseases remains unknown. CTEPH patients scheduled for pulmonary endarterectomy were pro...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1177/2045893217709763

    authors： Richter MJ,Gall H,Wittkämper G,Seeger W,Mayer E,Ghofrani HA,Guth S,Reichenberger F

    更新日期：2017-04-01 00:00:00

  • Obesity-related pulmonary arterial hypertension in rats correlates with increased circulating inflammatory cytokines and lipids and with oxidant damage in the arterial wall but not with hypoxia.

    abstract：:Obesity is causally linked to a number of comorbidities, including cardiovascular disease, diabetes, renal dysfunction, and cancer. Obesity has also been linked to pulmonary disorders, including pulmonary arterial hypertension (PAH). It was long believed that obesity-related PAH was the result of hypoventilation and h...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1086/678510

    authors： Irwin DC,Garat CV,Crossno JT Jr,MacLean PS,Sullivan TM,Erickson PF,Jackman MR,Harral JW,Reusch JE,Klemm DJ

    更新日期：2014-12-01 00:00:00

  • The genetics of pulmonary arterial hypertension in the post-BMPR2 era.

    abstract：:Pulmonary arterial hypertension (PAH) is a rapidly progressive and fatal disease for which there is an ever-expanding body of genetic and related pathophysiological information on disease pathogenesis. The most common single culprit gene known is BMPR2, and animal models of the disease in several forms exist. There is...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.4103/2045-8932.87293

    authors： Fessel JP,Loyd JE,Austin ED

    更新日期：2011-07-01 00:00:00

  • Rescue therapy with thrombolysis in patients with severe COVID-19-associated acute respiratory distress syndrome.

    abstract：:Acute respiratory distress syndrome in patients with Coronavirus disease 19 is associated with an unusually high incidence of pulmonary embolism and microthrombotic disease, with evidence for reduced fibrinolysis. We describe seven patients requiring invasive ventilation for COVID-19-associated acute respiratory distr...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1177/2045894020973906

    authors： Price LC,Garfield B,Bleakley C,Keeling AGM,Mcfadyen C,McCabe C,Ridge CA,Wort SJ,Price S,Arachchillage DJ

    更新日期：2020-12-15 00:00:00

  • Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension.

    abstract：:Oral treprostinil (TRE) is a prostacylin that is approved for the treatment of patients with pulmonary arterial hypertension (PAH). Dosing is approved for two or three times daily (t.i.d.); however, adverse effects, including gastrointestinal-related symptoms, may limit the ability to reach optimal doses. We report ou...

    journal_title：Pulmonary circulation

    pub_type：

    doi：10.1177/2045893217744512

    authors： Coons JC,Bunner C,Ishizawar DC,Risbano MG,Rivera-Lebron B,Mathier MA,Chan SY,Simon MA

    更新日期：2018-01-01 00:00:00

  • Derivation of a screening tool to identify patients with right ventricular dysfunction or tricuspid regurgitation after negative computerized tomographic pulmonary angiography of the chest.

    abstract：:Many dyspneic patients who undergo computerized tomographic pulmonary angiography (CTPA) for presumed acute pulmonary embolism (PE) have no identified cause for their dyspnea yet have persistent symptoms, leading to more CTPA scanning. Right ventricular (RV) dysfunction or overload can signal treatable causes of dyspn...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1086/679723

    authors： Kline JA,Russell FM,Lahm T,Mastouri RA

    更新日期：2015-03-01 00:00:00

  • BK channels in rat and human pulmonary smooth muscle cells are BKα-β1 functional complexes lacking the oxygen-sensitive stress axis regulated exon insert.

    abstract：:A loss of K+ efflux in pulmonary arterial smooth muscle cells (PASMCs) contributes to abnormal vasoconstriction and PASMC proliferation during pulmonary hypertension (PH). Activation of high-conductance Ca2+-activated (BK) channels represents a therapeutic strategy to restore K+ efflux to the affected PASMCs. However,...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1086/688838

    authors： Detweiler ND,Song L,McClenahan SJ,Versluis RJ,Kharade SV,Kurten RC,Rhee SW,Rusch NJ

    更新日期：2016-12-01 00:00:00

  • Serum soluble suppression of tumorigenicity-2 level associates with severity of pulmonary hypertension associated with uncorrected atrial septal defect.

    abstract：:Uncorrected atrial septal defect undergoes right ventricle chronic volume overload which may lead to pulmonary hypertension and Eisenmenger Syndrome. The soluble suppression of tumorigenicity-2 is a left ventricle strain biomarker; however, its role in right ventricle strain is unclear. This study aimed to investigate...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1177/2045894020915832

    authors： Pratama RS,Hartopo AB,Anggrahini DW,Dewanto VC,Dinarti LK

    更新日期：2020-05-26 00:00:00

  • Effects of exercise rehabilitation training on patients with pulmonary hypertension.

    abstract：:Pulmonary hypertension (PH) comprises a group of pathophysiological syndromes characterized by elevated pulmonary artery pressure and pulmonary vascular resistance, which lead to right ventricular overload, and even right heart failure. PH has a poor prognosis and severely leads to a decline in quality of life. Histor...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章,评审

    doi：10.1177/2045894020937129

    authors： Zhang X,Xu D

    更新日期：2020-07-07 00:00:00

  • A non-selective endothelin receptor antagonist bosentan modulates kinetics of bone marrow-derived cells in ameliorating pulmonary hypertension in mice.

    abstract：:The aim of this study was to investigate whether a dual endothelin receptor antagonist bosentan modulates the kinetics of bone marrow-derived stem cells in inhibiting the development of pulmonary hypertension. Bone marrow chimeric mice, transplanted with enhanced green fluorescent protein (eGFP)-positive bone marrow m...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1177/2045894020919355

    authors： Kato T,Mitani Y,Masuya M,Maruyama J,Sawada H,Ohashi H,Ikeyama Y,Otsuki S,Yodoya N,Shinohara T,Miyata E,Zhang E,Katayama N,Shimpo H,Maruyama K,Komada Y,Hirayama M

    更新日期：2020-05-14 00:00:00

  • Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries.

    abstract：:Limited data about the long-term prognosis and response to therapy in pulmonary arterial hypertension patients with World Health Organization functional class I/II symptoms are available. PubMed and Embase were searched for publications of observational registries and randomized, controlled trials in pulmonary arteria...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1177/2045894020935291

    authors： Kim NH,Fisher M,Poch D,Zhao C,Shah M,Bartolome S

    更新日期：2020-11-25 00:00:00

  • Advanced risk stratification of intermediate risk group in pulmonary arterial hypertension.

    abstract：:In 301 treatment-naïve patients with pulmonary arterial hypertension stratified by the European Society of Cardiology/European Respiratory Society risk score, further stratification of intermediate-risk patients based on six-minute walk distance and the tricuspid annular plane systolic excursion/systolic pulmonary art...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1177/2045894020961739

    authors： Yogeswaran A,Richter MJ,Sommer N,Ghofrani HA,Seeger W,Tello K,Gall H

    更新日期：2020-10-07 00:00:00

  • Prediction value of pulmonary hypertension in newly identified left ventricular dysfunction among adult patients after patent ductus arteriosus closure.

    abstract：:The present study aimed to propose the pulmonary hypertension for predicting left ventricular dysfunction in adults after patent ductus arteriosus closure. A total of 183 patients (age ≥18 years) after patent ductus arteriosus occlusion were retrospectively collected in this study. In brief, pre-, post-procedure and s...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1177/2045894019888428

    authors： Chen PY,Luo DL,Li HZ,Fei HW,Huang T,Huang YG,Chen JM,Zhuang J,He PC,Zhang CJ

    更新日期：2019-11-15 00:00:00

  • Pulmonary tumor thrombotic microangiopathy: a systematic review.

    abstract：:Pulmonary tumor thrombotic microangiopathy (PTTM) is a fatal disease process in which pulmonary hypertension (PH) develops in the setting of malignancy. The purpose of this study is to present a detailed analysis of cases of PTTM reported in literature in the hopes of achieving more ante-mortem diagnoses. We conducted...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1177/2045894019851000

    authors： Godbole RH,Saggar R,Kamangar N

    更新日期：2019-04-01 00:00:00

  • Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension.

    abstract：:Our aim is to assess the safety and potential efficacy of a novel treatment paradigm in pulmonary arterial hypertension (PAH), immunomodulation by blocking interleukin-6 (IL6) signaling with the IL6 receptor antagonist, tocilizumab. Inflammation and autoimmunity are established as important in PAH pathophysiology. One...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1177/2045893217735820

    authors： Hernández-Sánchez J,Harlow L,Church C,Gaine S,Knightbridge E,Bunclark K,Gor D,Bedding A,Morrell N,Corris P,Toshner M

    更新日期：2018-01-01 00:00:00

  • Dosing characteristics of oral treprostinil in real-world clinical practice.

    abstract：:Pharmacokinetic studies with oral treprostinil demonstrate that three times daily (TID) dosing reduces peak-to-trough plasma trepostinil fluctuations compared with twice daily (BID) dosing. TID dosing may allow for faster titration, higher total daily doses, and potentially improve the tolerability of oral trepostinil...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1177/2045894018770654

    authors： Balasubramanian VP,Messick CR,Broderick M,Nelsen AC

    更新日期：2018-04-01 00:00:00

  • Neonatal oxygenation, pulmonary hypertension, and evolutionary adaptation to high altitude (2013 Grover Conference series).

    abstract：:Andeans and Tibetans have less altitude reduction in birth weight than do shorter-resident groups, but only Tibetans are protected from pulmonary hypertension and chronic mountain sickness (CMS). We hypothesized that differences in neonatal oxygenation were involved, with arterial O2 saturation (SaO2) being highest in...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章,评审

    doi：10.1086/679719

    authors： Niermeyer S,Andrade-M MP,Vargas E,Moore LG

    更新日期：2015-03-01 00:00:00

  • Shared gene expression patterns in mesenchymal progenitors derived from lung and epidermis in pulmonary arterial hypertension: identifying key pathways in pulmonary vascular disease.

    abstract：:Rapid access to lung-derived cells from stable subjects is a major challenge in the pulmonary hypertension field, given the relative contraindication of lung biopsy. In these studies, we sought to demonstrate the importance of evaluating a cell type that actively participates in disease processes, as well as the poten...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1086/688314

    authors： Gaskill C,Marriott S,Pratap S,Menon S,Hedges LK,Fessel JP,Kropski JA,Ames D,Wheeler L,Loyd JE,Hemnes AR,Roop DR,Klemm DJ,Austin ED,Majka SM

    更新日期：2016-12-01 00:00:00

  • Characterization of altered patterns of endothelial progenitor cells in sickle cell disease related pulmonary arterial hypertension.

    abstract：:Endothelial dysfunction plays an important role in the pathogenesis of pulmonary arterial hypertension (PAH) in sickle cell disease (SCD). A variety of evidence suggests that circulating endothelial progenitor cells (EPCs) play an integral role in vascular repair. We hypothesized that SCD patients with PAH are deficie...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.4103/2045-8932.94834

    authors： Anjum F,Lazar J,Zein J,Jamaleddine G,Demetis S,Wadgaonkar R

    更新日期：2012-01-01 00:00:00

  • Mechanical forces stimulate endothelial microparticle generation via caspase-dependent apoptosis-independent mechanism.

    abstract：:Microparticle release by vascular endothelium has been implicated in various cardiovascular pathologies. Ventilator-induced lung injury (VILI) is a life-threatening complication of mechanical ventilation at high tidal volumes associated with excessive mechanical stretch of pulmonary vascular endothelial cells. However...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.4103/2045-8932.109921

    authors： Vion AC,Birukova AA,Boulanger CM,Birukov KG

    更新日期：2013-01-01 00:00:00

  • Impact of diabetes on survival and right ventricular compensation in pulmonary arterial hypertension.

    abstract：:Insulin resistance is highly prevalent in pulmonary arterial hypertension (PAH) patients. However, the long-term impact of diabetes mellitus (DM) on survival in PAH is unclear. Insulin resistance and DM are associated with left ventricular steatosis and dysfunction, but whether the right ventricle (RV) might be affect...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1086/675994

    authors： Benson L,Brittain EL,Pugh ME,Austin ED,Fox K,Wheeler L,Robbins IM,Hemnes AR

    更新日期：2014-06-01 00:00:00

  • Survey of practices in relation to chronic pulmonary hypertension in neonates in the Canadian Neonatal Network and the National Institute of Child Health and Human Development Neonatal Research Network.

    abstract：:Current knowledge gaps pertaining to diagnosis and management of neonatal chronic pulmonary hypertension (cPH) may result in significant variability in clinical practice. The objective of the study is to understand cPH management practices in neonatal intensive care units affiliated with the Canadian Neonatal Network ...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1177/2045894020937126

    authors： Baczynski M,Bell EF,Finan E,McNamara PJ,Jain A

    更新日期：2020-07-16 00:00:00

  • Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial.

    abstract：:Inhaled iloprost is an effective therapy for patients with pulmonary arterial hypertension (PAH); however, some patients experience extended inhalation times when using the V10 formulation (10.0 µg/mL) to deliver a 5 -µg dose (at mouthpiece) and are at risk of incomplete inhalations and reduced inhalation frequency. V...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1177/2045894018798921

    authors： Richter MJ,Stollfuß B,Roitenberg A,Kleinjung F,Graeff V,Berghaus S,Müller C,Ghofrani HA

    更新日期：2018-10-01 00:00:00

  • Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension.

    abstract：:This manuscript on endpoints incorporates the broad experience of members of Pulmonary Vascular Research Institute's Innovative Drug Development Initiative as an open debate platform for academia, the pharmaceutical industry and regulatory experts surrounding the future design of clinical trials in pulmonary hypertens...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1177/2045894020962960

    authors： Sitbon O,Nikkho S,Benza R,Cq Deng C,W Farber H,Gomberg-Maitland M,Hassoun P,Meier C,Pepke-Zaba J,Prasad K,Seeger W,Corris PA

    更新日期：2020-11-18 00:00:00

  • Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a population-based cohort study in England.

    abstract：:Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of unresolved organised pulmonary emboli/thrombi obstructing the major pulmonary arteries. The aim of this study was to estimate the incidence and risk factors of CTEPH in a cohort with first venous thromboembolism (VTE). This was a population-bas...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1177/2045894018791358

    authors： Martinez C,Wallenhorst C,Teal S,Cohen AT,Peacock AJ

    更新日期：2018-07-01 00:00:00

  • Atrial arrhythmias in chronic lung disease-associated pulmonary hypertension.

    abstract：:Atrial arrhythmias are common during episodes of acute respiratory failure in patients with chronic lung disease-associated pulmonary hypertension. Expert opinion suggests that management of atrial arrhythmias in patients with pulmonary hypertension should aim to restore sinus rhythm. This is clinically challenging in...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章,评审

    doi：10.1177/2045894020910685

    authors： Vahdatpour CA,Luebbert JJ,Palevsky HI

    更新日期：2020-03-09 00:00:00

  • Levosimendan in pulmonary hypertension and right heart failure.

    abstract：:Pulmonary hypertension is a multifactorial disease with a high morbidity and mortality. Right ventricular function is the most important predictor of morbidity and mortality in patients suffering from pulmonary hypertension, but currently there are no approved treatments directly supporting the failing right ventricle...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1177/2045894018790905

    authors： Hansen MS,Andersen A,Nielsen-Kudsk JE

    更新日期：2018-07-01 00:00:00

  • Adverse physiologic effects of Western diet on right ventricular structure and function: role of lipid accumulation and metabolic therapy.

    abstract：:Little is known about the impact of metabolic syndrome (MS) on right ventricular (RV) structure and function. We hypothesized that mice fed a Western diet (WD) would develop RV lipid accumulation and impaired RV function, which would be ameliorated with metformin. Male C57/Bl6 mice were fed a WD or standard rodent die...

    journal_title：Pulmonary circulation

    pub_type： 杂志文章

    doi：10.1177/2045894018817741

    authors： Brittain EL,Talati M,Fortune N,Agrawal V,Meoli DF,West J,Hemnes AR

    更新日期：2019-01-01 00:00:00